Pharmacotherapy of regional melanoma therapy

Bibliography

• Jemal A, Siegel R, Ward E, Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49
   PubMed Web of Science ®Google Scholar
• Weinstock MA. Do sunscreens increase or decrease melanoma risk: an epidemiologic evaluation. J Investig Dermatol Symp Proc 1999;4:97-100
   PubMed Web of Science ®Google Scholar
• Pawlik TM, Ross MI, Johnson MM, Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann Surg Oncol 2005;12:587-96
   PubMed Web of Science ®Google Scholar
• Balch CM, Buzaid AC, Soong SJ, Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-48
   PubMed Web of Science ®Google Scholar
• Meier F, Will S, Ellwanger U, Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol 2002;147:62-70
   PubMed Web of Science ®Google Scholar
• Cascinelli N, Bufalino R, Marolda R, Regional non-nodal metastases of cutaneous melanoma. Eur J Surg Oncol 1986;12:175-80
   PubMedGoogle Scholar
• Calabro A, Singletary SE, Balch CM. Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases. Arch Surg 1989;124:1051-5
   PubMedGoogle Scholar
• Zogakis TG, Bartlett DL, Libutti SK, Factors affecting survival after complete response to isolated limb perfusion in patients with in-transit melanoma. Ann Surg Oncol 2001;8:771-8
   PubMed Web of Science ®Google Scholar
• Dong XD, Tyler D, Johnson JL, Analysis of prognosis and disease progression after local recurrence of melanoma. Cancer 2000;88:1063-71
   PubMedGoogle Scholar
• Bhatia S, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: an overview. Oncology (Williston Park) 2009;23:488-96
   PubMed Web of Science ®Google Scholar
• Creech O Jr, Ryan RF, Krementz ET. Regional chemotherapy by isolated perfusion in the treatment of melanoma of the extremities. Plast Reconstr Surg Transplant Bull 1961;28:333-46
   PubMedGoogle Scholar
• Creech O Jr, Krementz ET, Ryan RF, Winblad JN. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. Ann Surg 1958;148:616-32
   PubMed Web of Science ®Google Scholar
• Cavaliere R, Ciocatto EC, Giovanella BC, Selective heat sensitivity of cancer cells. Biochemical and clinical studies. Cancer 1967;20:1351-81
   PubMed Web of Science ®Google Scholar
• Stehlin JS Jr. Hyperthermic perfusion with chemotherapy for cancers of the extremities. Surg Gynecol Obstet 1969;129:305-8
   PubMedGoogle Scholar
• Ghussen F, Kruger I, Smalley RV, Groth W. Hyperthermic perfusion with chemotherapy for melanoma of the extremities. World J Surg 1989;13:598-602
   PubMed Web of Science ®Google Scholar
• Dahl O, Mella O. Hyperthermia and Chemotherapeutic Agents. New York: Taylor & Francis; 1990
   Google Scholar
• Hahn GM. Potential for therapy of drugs and hyperthermia. Cancer Res 1979;39:2264-8
   PubMed Web of Science ®Google Scholar
• Wallah DFH. Basic mechanisms of tumor thermotherapy. J Mol Med 1977;17:381-403
   Google Scholar
• Huang SK, Stauffer PR, Hong K, Liposomes and hyperthermia in mice: increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes. Cancer Res 1994;54:2186-91
   PubMed Web of Science ®Google Scholar
• Beasley GM, Petersen RP, Yoo J, Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol 2008;15:2195-205
   PubMed Web of Science ®Google Scholar
• Minor DR, Allen RE, Alberts D, A clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for melanoma. Cancer 1985;55:2638-44
   PubMed Web of Science ®Google Scholar
• Di Filippo F, Calabro A, Giannarelli D, Prognostic variables in recurrent limb melanoma treated with hyperthermic antiblastic perfusion. Cancer 1989;63:2551-61
   PubMed Web of Science ®Google Scholar
• Klaase JM, Kroon BB, van Geel AN, Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan. Surgery 1994;115:39-45
   PubMed Web of Science ®Google Scholar
• Skene AI, Bulman AS, Williams TR, Hyperthermic isolated perfusion with melphalan in the treatment of advanced malignant melanoma of the lower limb. Br J Surg 1990;77:765-7
   PubMed Web of Science ®Google Scholar
• Grunhagen DJ, Brunstein F, Graveland WJ, One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases. Ann Surg 2004;240:939-47; discussion 47-8
   PubMed Web of Science ®Google Scholar
• Sanki A, Kam PC, Thompson JF. Long-term results of hyperthermic, isolated limb perfusion for melanoma: a reflection of tumor biology. Ann Surg 2007;245:591-6
   PubMed Web of Science ®Google Scholar
• Thompson JF, Kam PC, Waugh RC, Harman CR. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. Semin Surg Oncol 1998;14:238-47
   PubMed Web of Science ®Google Scholar
• Thompson JF, Waugh RC, Saw RPM, Isolated limb infusion with melphalan for recurrent limb melanoma: a simple alternative to isolated limb perfusion. Regional Cancer Treat 1994;7:188-92
   Google Scholar
• Beasley GM, Caudle A, Petersen RP, A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. J Am Coll Surg 2009;208:706-15; discussion 15-17
   PubMed Web of Science ®Google Scholar
• Santillan AA, Delman KA, Beasley GM, Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis. Ann Surg Oncol 2009;16:2570-8
   PubMed Web of Science ®Google Scholar
• Kroon HM, Moncrieff M, Kam PC, Thompson JF. Outcomes following isolated limb infusion for melanoma. A 14-year experience. Ann Surg Oncol 2008;15:3003-13
   PubMed Web of Science ®Google Scholar
• Benckhuijsen C, Kroon BB, van Geel AN, Wieberdink J. Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics. Eur J Surg Oncol 1988;14:157-63
   PubMed Web of Science ®Google Scholar
• Thompson JF, Lai DT, Ingvar C, Maximizing efficacy and minimizing toxicity in isolated limb perfusion for melanoma. Melanoma Res 1994;4S:45-50
   Google Scholar
• Wu ZY, Smithers BM, Roberts MS. Tissue and perfusate pharmacokinetics of melphalan in isolated perfused rat hindlimb. J Pharmacol Exp Ther 1997;282:1131-8
   PubMed Web of Science ®Google Scholar
• Padussis JC, Steerman SN, Tyler DS, Mosca PJ. Pharmacokinetics and drug resistance of melphalan in regional chemotherapy: ILP versus ILI. Int J Hyperthermia 2008;24:239-49
   PubMed Web of Science ®Google Scholar
• Eggermont AM, de Wilt JH, ten Hagen TL. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol 2003;4:429-37
   PubMed Web of Science ®Google Scholar
• Luce JK. Chemotherapy of malignant melanoma. Cancer 1972;30:1604-15
   PubMed Web of Science ®Google Scholar
• Roberts MS, Wu ZY, Siebert GA, Saturable dose-response relationships for melphalan in melanoma treatment by isolated limb infusion in the nude rat. Melanoma Res 2001;11:611-18
   PubMed Web of Science ®Google Scholar
• Kroon HM, Moncrieff M, Kam PC, Thompson JF. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients. Ann Surg Oncol 2009;16:1184-92
   PubMed Web of Science ®Google Scholar
• Taber SW, Polk HC Jr. Mortality, major amputation rates, and leukopenia after isolated limb perfusion with phenylalanine mustard for the treatment of melanoma. Ann Surg Oncol 1997;4:440-5
   PubMed Web of Science ®Google Scholar
• Cheng TY, Grubbs E, Abdul-Wahab O, Marked variability of melphalan plasma drug levels during regional hyperthermic isolated limb perfusion. Am J Surg 2003;186:460-7
   PubMed Web of Science ®Google Scholar
• Lindner P, Doubrovsky A, Kam PC, Thompson JF. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol 2002;9:127-36
   PubMed Web of Science ®Google Scholar
• Vrouenraets BC, Hart GA, Eggermont AM, Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma. J Am Coll Surg 1999;188:522-30
   PubMed Web of Science ®Google Scholar
• Beasley GM, McMahon N, Sanders G, A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma. Cancer 2009;115(20):4766
   Google Scholar
• Engler HS, Sweat RD. Volumetric arm measurements: technique and results. Am Surg 1962;28:465-8
   PubMedGoogle Scholar
• McMahon N, Cheng TY, Beasley GM, Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity? Ann Surg Oncol 2009;16:953-61
   PubMed Web of Science ®Google Scholar
• Parsons PG, Carter FB, Morrison L, Regius MS. Mechanism of melphalan resistance developed in vitro in human melanoma cells. Cancer Res 1981;41:1525-34
   PubMed Web of Science ®Google Scholar
• Wieberdink J, Benckhuysen C, Braat RP, Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions. Eur J Cancer Clin Oncol 1982;18:905-10
   PubMedGoogle Scholar
• Clark J, Grabs AJ, Parsons PG, Melphalan uptake, hyperthermic synergism and drug resistance in a human cell culture model for the isolated limb perfusion of melanoma. Melanoma Res 1994;4:365-70
   PubMed Web of Science ®Google Scholar
• Kroon BB, Noorda EM, Vrouenraets BC, Isolated limb perfusion for melanoma. Surg Oncol Clin N Am 2008;17:785-94, viii-ix
   PubMedGoogle Scholar
• Brady MS, Brown K, Patel A, A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity. Ann Surg Oncol 2006;13:1123-9
   PubMed Web of Science ®Google Scholar
• Dufour M, Panasci LC, St Germain J, Boulet L. Effects of amino acids on the transport and cytotoxicity of melphalan by human bone marrow cells and human tumor cells. Cancer Chemother Pharmacol 1985;15:125-31
   PubMed Web of Science ®Google Scholar
• Vistica DT, Toal JN, Rabinovitz M. Amino acid-conferred protection against melphalan – characterization of melphalan transport and correlation of uptake with cytotoxicity in cultured L1210 murine leukemia cells. Biochem Pharmacol 1978;27:2865-70
   PubMed Web of Science ®Google Scholar
• Ichihashi N, Kitajima Y. Chemotherapy induces or increases expression of multidrug resistance-associated protein in malignant melanoma cells. Br J Dermatol 2001;144:745-50
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Makki A, Stahr C, Membrane transport proteins associated with drug resistance expressed in human melanoma. Am J Pathol 1995;147:1545-52
   PubMed Web of Science ®Google Scholar
• Serrone L, Hersey P. The chemoresistance of human malignant melanoma: an update. Melanoma Res 1999;9:51-8
   PubMed Web of Science ®Google Scholar
• Depeille P, Cuq P, Passagne I, Combined effects of GSTP1 and MRP1 in melanoma drug resistance. Br J Cancer 2005;93:216-23
   PubMed Web of Science ®Google Scholar
• Stein U, Jurchott K, Schlafke M, Hohenberger P. Expression of multidrug resistance genes MVP, MDR1, and MRP1 determined sequentially before, during, and after hyperthermic isolated limb perfusion of soft tissue sarcoma and melanoma patients. J Clin Oncol 2002;20:3282-92
   PubMed Web of Science ®Google Scholar
• McClean S, Hill BT. An overview of membrane, cytosolic and nuclear proteins associated with the expression of resistance to multiple drugs in vitro. Biochim Biophys Acta 1992;1114:107-27
   PubMed Web of Science ®Google Scholar
• Suzukake K, Vistica BP, Vistica DT. Dechlorination of L-phenylalanine mustard by sensitive and resistant tumor cells and its relationship to intracellular glutathione content. Biochem Pharmacol 1983;32:165-7
   PubMed Web of Science ®Google Scholar
• Dulik DM, Fenselau C, Hilton J. Characterization of melphalan-glutathione adducts whose formation is catalyzed by glutathione transferases. Biochem Pharmacol 1986;35:3405-9
   PubMed Web of Science ®Google Scholar
• Buller AL, Clapper ML, Tew KD. Glutathione S-transferases in nitrogen mustard-resistant and -sensitive cell lines. Mol Pharmacol 1987;31:575-8
   PubMed Web of Science ®Google Scholar
• Suzukake K, Petro BJ, Vistica DT. Reduction in glutathione content of L-PAM resistant L1210 Cells confers drug sensitivity. Biochem Pharmacol 1982;31:121-4
   PubMed Web of Science ®Google Scholar
• Grubbs EG, Abdel-Wahab O, Cheng TY, In-transit melanoma: the role of alkylating-agent resistance in regional therapy. J Am Coll Surg 2004;199:419-27
   PubMed Web of Science ®Google Scholar
• Harkey MA, Czerwinski M, Slattery J, Kiem HP. Overexpression of glutathione-S-transferase, MGSTII, confers resistance to busulfan and melphalan. Cancer Invest 2005;23:19-25
   PubMed Web of Science ®Google Scholar
• Strumeyer DH, Bloch K. Some properties of gamma-glutamylcysteine synthetase. J Biol Chem 1960;235:PC27-
   PubMedGoogle Scholar
• Griffith OW, Meister A. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J Biol Chem 1979;254:7558-60
   PubMed Web of Science ®Google Scholar
• Biroccio A, Benassi B, Fiorentino F, Zupi G. Glutathione depletion induced by c-Myc downregulation triggers apoptosis on treatment with alkylating agents. Neoplasia 2004;6:195-206
   PubMed Web of Science ®Google Scholar
• Bailey HH, Ripple G, Tutsch KD, Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan. J Natl Cancer Inst 1997;89:1789-96
   PubMed Web of Science ®Google Scholar
• Prezioso JA, FitzGerald GB, Wick MM. Melanoma cytotoxicity of buthionine sulfoximine (BSO) alone and in combination with 3,4-dihydroxybenzylamine and melphalan. J Invest Dermatol 1992;99:289-93
   PubMed Web of Science ®Google Scholar
• Grant DF, Bessho T, Reardon JT. Nucleotide excision repair of melphalan monoadducts. Cancer Res 1998;58:5196-200
   PubMed Web of Science ®Google Scholar
• Friedman HS, Dolan ME, Pegg AE, Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res 1995;55:2853-7
   PubMed Web of Science ®Google Scholar
• Kroon HM, Thompson JF. Isolated limb infusion: a review. J Surg Oncol 2009;100:169-77
   PubMed Web of Science ®Google Scholar
• Thompson JF, Gianoutsos MP. Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs. World J Surg 1992;16:227-33
   PubMed Web of Science ®Google Scholar
• Wile AG, Guilmette E, Friedberg H, Mason GR. A model of experimental isolation perfusion using cis-platinum. J Surg Oncol 1982;21:37-41
   PubMedGoogle Scholar
• Aigner K, Hild P, Henneking K, Regional perfusion with cis-platinum and dacarbazine. Recent Results Cancer Res 1983;86:239-45
   PubMedGoogle Scholar
• Klein ES, Ben-Ari GY. Isolation perfusion with cisplatin for malignant melanoma of the limbs. Cancer 1987;59:1068-71
   PubMed Web of Science ®Google Scholar
• Roseman JM. Effective management of extremity cancers using cisplatin and etoposide in isolated limb perfusions. J Surg Oncol 1987;35:170-2
   PubMedGoogle Scholar
• Pommier RF, Moseley HS, Cohen J, Pharmacokinetics, toxicity, and short-term results of cisplatin hyperthermic isolated limb perfusion for soft-tissue sarcoma and melanoma of the extremities. Am J Surg 1988;155:667-71
   PubMed Web of Science ®Google Scholar
• Hajarizadeh H, Mueller CR, Woltering EA, Phase I – II trial of hyperthermic isolated limb perfusion with cisplatin in the treatment of high risk malignant melanoma of the extremities. Melanoma Res 1991;1:55-61
   PubMedGoogle Scholar
• Santinami M, Belli F, Cascinelli N, Seven years experience with hyperthermic perfusions in extracorporeal circulation for melanoma of the extremities. J Surg Oncol 1989;42:201-8
   PubMed Web of Science ®Google Scholar
• Coit DG, Bajorin DF, Menendez-Botet C. A phase I trial of hyperthermic isolation limb perfusion (HILP) using cisplatin (CDDP) for metastatic melanoma. Proc ASCO 1991;10:294
   Google Scholar
• Ueno T, Ko SH, Grubbs E, Modulation of chemotherapy resistance in regional therapy: a novel therapeutic approach to advanced extremity melanoma using intra-arterial temozolomide in combination with systemic O6-benzylguanine. Mol Cancer Ther 2006;5:732-8
   PubMed Web of Science ®Google Scholar
• Thompson JF, Hunt JA, Shannon KF, Kam PC. Frequency and duration of remission after isolated limb perfusion for melanoma. Arch Surg 1997;132:903-7
   PubMed Web of Science ®Google Scholar
• Carswell EA, Old LJ, Kassel RL, An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975;72:3666-70
   PubMed Web of Science ®Google Scholar
• Green S, Dobrjansky A, Carswell EA, Partial purification of a serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1976;73:381-5
   PubMed Web of Science ®Google Scholar
• Williamson BD, Carswell EA, Rubin BY, Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon. Proc Natl Acad Sci USA 1983;80:5397-401
   PubMed Web of Science ®Google Scholar
• van Horssen R, Ten Hagen TL, Eggermont AM. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist 2006;11:397-408
   PubMed Web of Science ®Google Scholar
• Posner MC, Lienard D, Lejeune FJ, Hyperthermic isolated limb perfusion with tumor necrosis factor alone for melanoma. Cancer J Sci Am 1995;1:274-80
   PubMedGoogle Scholar
• Brouckaert PG, Leroux-Roels GG, Guisez Y, In vivo anti-tumour activity of recombinant human and murine TNF, alone and in combination with murine IFN-gamma, on a syngeneic murine melanoma. Int J Cancer 1986;38:763-9
   PubMed Web of Science ®Google Scholar
• Lienard D, Ewalenko P, Delmotte JJ, High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992;10:52-60
   PubMed Web of Science ®Google Scholar
• Cornett WR, McCall LM, Petersen RP, Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol 2006;24:4196-201
   PubMed Web of Science ®Google Scholar
• Lejeune FJ, Eggermont AM. Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs. J Clin Oncol 2007;25:1449-50; author reply 50-1
   PubMed Web of Science ®Google Scholar
• Garrido-Laguna I, Ponz M, Espinos J. Is there any reason to delay introduction of tumor necrosis factor in the management of in-transit metastasis of unresectable melanoma? J Clin Oncol 2007;25:1149-51
   PubMed Web of Science ®Google Scholar
• Di Filippo F, Giacomini P, Rossi CR, Prognostic factors influencing tumor response, locoregional control and survival, in melanoma patients with multiple limb in-transit metastases treated with TNFalpha-based isolated limb perfusion. In Vivo 2009;23:347-52
   PubMedGoogle Scholar
• Augustine CK, Yoshimoto Y, Gupta M, Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment. Cancer Res 2008;68:3777-84
   PubMed Web of Science ®Google Scholar
• Hsu MY, Wheelock MJ, Johnson KR, Herlyn M. Shifts in cadherin profiles between human normal melanocytes and melanomas. J Investig Dermatol Symp Proc 1996;1:188-94
   PubMedGoogle Scholar
• Hsu MY, Meier FE, Nesbit M, E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. Am J Pathol 2000;156:1515-25
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C, Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54
   PubMed Web of Science ®Google Scholar
• Eisen T, Ahmad T, Gore M, Phase I trial of Bay 43-9006 (Sorafenib) combined with DTIC in metastatic melanoma patients. Proc Am Soc Clin Oncol 2005;712:7508
   Google Scholar
• Lorigan P, Corrie P, Chao D, Phase II trial of sorafenib combined with dacarbazine in metastatic melanoma patients. J Clin Oncol 2006;24(18 suppl):2178-85
   Google Scholar
• Hauschild A, Agarwala SS, Trefzer U, Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009;27:2823-30
   PubMed Web of Science ®Google Scholar
• Niu G, Bowman T, Huang M, Roles of activated Src and Stat3 signaling in melanoma tumor cell growth. Oncogene 2002;21:7001-10
   PubMed Web of Science ®Google Scholar
• Niu G, Wright KL, Huang M, Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002;21:2000-8
   PubMed Web of Science ®Google Scholar
• Friedman HS, Prados MD, Wen PY, Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27(28):4733-4740
   Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42
   PubMed Web of Science ®Google Scholar
• Miller K, Wang M, Gralow J, Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76
   PubMed Web of Science ®Google Scholar
• Pallis AG, Serfass L, Dziadziusko R, Targeted therapies in the treatment of advanced/metastatic NSCLC. Eur J Cancer 2009;45:2473-87
   PubMed Web of Science ®Google Scholar
• Terheyden P, Hofmann MA, Weininger M, Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanoma. J Cancer Res Clin Oncol 2007;133:897-901
   PubMed Web of Science ®Google Scholar
• Jaissle GB, Ulmer A, Henke-Fahle S, Suppression of melanoma-associated neoangiogenesis by bevacizumab. Arch Dermatol 2008;144:525-7
   PubMedGoogle Scholar
• Varker KA, Biber JE, Kefauver C, A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol 2007;14:2367-76
   PubMed Web of Science ®Google Scholar
• Thompson JF, Kam PC. Isolated limb infusion for melanoma: a simple but effective alternative to isolated limb perfusion. J Surg Oncol 2004;88:1-3
   PubMed Web of Science ®Google Scholar